Form 4: BioCardia CEO Acquires Shares
Insider Transaction Filing
BioCardia, Inc. President and CEO Peter Altman acquired a total of 7,500 shares of common stock across three transactions in early July 2026.
Summary
- Peter Altman, President and CEO of BioCardia, Inc., acquired a total of 7,500 shares of common stock through multiple transactions between July 8, 2026, and July 10, 2026.
- The acquisitions occurred at prices ranging from $0.90 to $0.97 per share.
- Following these transactions, Altman's beneficial ownership of BioCardia common stock increased to 369,485 shares.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a moderately positive development due to the CEO's direct investment in the company, signaling confidence, though the absolute number of shares acquired is relatively small in the context of total outstanding shares.
Positives
- The CEO's acquisition of company stock signals confidence in the company's future prospects.
- The transactions were executed at prices below $1.00, potentially indicating a favorable entry point for the CEO.
- The CEO's beneficial ownership has increased, aligning his interests further with shareholders.
Future Outlook
No specific forward-looking statements or guidance were provided in this filing.
Industry Context
StockSavvy.ai notes that insider buying, particularly by a CEO, is often interpreted as a positive signal by the market, suggesting management's belief in the company's undervaluation or future growth potential. This is particularly relevant in the biotechnology sector where stock performance can be volatile and heavily influenced by clinical trial results and regulatory approvals.
Stakeholder Impact
- Shareholders may view the CEO's stock purchase as a positive indicator of management's confidence in the company's future performance.
- Employees may be encouraged by the CEO's investment, potentially boosting morale and alignment with company goals.
Key Dates
| Date | Description |
|---|---|
| 07/08/2026 | Earliest transaction date for stock acquisition by Peter Altman. |
| 07/08/2026 | Transaction date for the acquisition of 5,500 shares of common stock by Peter Altman. |
| 07/09/2026 | Transaction date for the acquisition of 1,000 shares of common stock by Peter Altman. |
| 07/10/2026 | Transaction date for the acquisition of 1,000 shares of common stock by Peter Altman. |
| 07/10/2026 | Date of signature for the Form 4 filing. |
Recommendation
holdThe filing indicates a positive signal from the CEO's stock purchase, suggesting confidence. However, without broader financial performance data or strategic updates, a 'hold' recommendation is prudent, allowing for further analysis of the company's operational and financial health.
Keywords
BioCardia, BCDA, Form 4, Insider Trading, Stock Acquisition, Peter Altman, CEO, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.